Advertisement
With this certificate, China-Biotics' new Qingpu facility is manufacturingall probiotic products under the nation's strict GMP standard. Thiscertificate is valid through March 28, 2013 and is renewable. The Company'sQingpu facility features a 150 metric ton annual production capacity withproduction expected to reach a run rate of 75 metric tons by the end of 2010.
Advertisement
Mr. Jinan Song, Chairman and Chief Executive Officer of China-Biotics,commented, "We are excited that our new state-of-the-art facility, featuringour own proprietary fermentation technologies and highly automated processingmodules, has met the stringent requirements of the SFDA and it serves as atestament to our production management and quality control. GMP approval forprobiotic products is one of the prerequisite metrics for a supplier to majordiary producers in China. As probiotics are increasingly used in yogurt andmilk powder in China, we now look forward to ramping up our commercialproduction to meet the growing demand for probiotic products nationwide."
About China-Biotics
China-Biotics, Inc. ("China-Biotics," "the Company"), a leadingmanufacturer of biotechnology products and supplements, engages in theresearch, development, marketing and distribution of probiotics dietarysupplements in China. Through its wholly owned subsidiary, Shanghai ShiningBiotechnology Co., Ltd., the Company develops and produces its proprietaryproduct portfolio including live microbial nutritional supplements under the"Shining" brand. Currently, the products are sold OTC through largedistributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiangprovince. In February 2010, China-Biotics began its commercial production inChina's largest probiotics production facility to meet growing demand in China.For more information, please visit http://www.chn-biotics.com .
Safe Harbor Statement
The information in this release contains forward-looking statements whichinvolve risks and uncertainties, including statements regarding the Company'scapital needs, business strategy and expectations. Any statements containedherein that are not statements of historical fact may be deemed to beforward-looking statements, which may be identified by terminology such as"may," "should," "will," "expect," "plan," "intend," "anticipate," "believe,""estimate," "predict," "potential," "forecast," "project," or "continue," thenegative of such terms or other comparable terminology. Readers should notrely on forward-looking statements as predictions of future events or results.Any or all of the Company's forward-looking statements may turn out to bewrong. They can be affected by inaccurate assumptions, risks and uncertaintiesand other factors which could cause actual events or results to be materiallydifferent from those expressed or implied in the forward-looking statements.In evaluating these statements, readers should consider various factors,including the risks described in "Item 1A. Risk Factors" beginning on page 15and elsewhere in the Company's 2009 Annual Report on Form 10-K. These factorsmay cause the Company's actual results to differ materially from anyforward-looking statement. In addition, new factors emerge from time to timeand it is not possible for the Company to predict all factors that may causeactual results to differ materially from those contained in any forward-looking statements. The Company disclaims any obligation to publicly updateany forward-looking statements to reflect events or circumstances after thedate of this document, except as required by applicable law.For more information, please contact: Travis Cai Chief Financial Officer China-Biotics, Inc. Email: [email protected] Kevin Theiss Grayling Tel: +1-646-284-9409 Email: [email protected]
SOURCE China-Biotics, Inc.
